The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tyurina A.N.

Burdenko Neurosurgical Center

Vikhrova N.B.

Burdenko Neurosurgical Center

Batalov A.I.

Burdenko Neurosurgical Center

Kalaeva D.B.

Burdenko Center of Neurosurgery;
National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)

Shults E.I.

Research Practical Clinical Center of Diagnosis and Telemedicine Technologies

Postnov A.A.

Burdenko National Medical Scientific Center for Neurosurgery;
National Research Nuclear University MEPhI (Moscow Engineering Physics Institute);
Lebedev Physical Institute of the Russian Academy of Sciences

Pronin I.N.

Burdenko Neurosurgical Center

Radiological biomarkers of brain gliomas

Authors:

Tyurina A.N., Vikhrova N.B., Batalov A.I., Kalaeva D.B., Shults E.I., Postnov A.A., Pronin I.N.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2022;86(6): 121‑126

DOI: 10.17116/neiro202286061121

Read: 3060 times

Download PDF (RU)
Download PDF
Contact the author
Table of contents

RADIOLOGICAL BIOMARKERS OF BRAIN GLIOMAS
RADIOLOGICAL BIOMARKERS OF BRAIN GLIOMAS

To cite this article:

Tyurina AN, Vikhrova NB, Batalov AI, Kalaeva DB, Shults EI, Postnov AA, Pronin IN. Radiological biomarkers of brain gliomas. Burdenko's Journal of Neurosurgery. 2022;86(6):121‑126. (In Russ., In Engl.)
https://doi.org/10.17116/neiro202286061121

Подписка 2025 Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко (Burdenko's Journal of Neurosurgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The expe­rience of diagnosing Alzheimer’s disease based on the study of cere­brospinal fluid biomarkers. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):91-97
Diagnoctic test accu­racy of nucleated red blood cells in non-hematologic inte­nsive care patients (meta-analysis). Russian Journal of Anesthesiology and Reanimatology. 2025;(2):68-82
Prognostic significance of NT-proBNP and sST2 in patients with chro­nic heart failure and redu­ced ejection fraction after previous deco­mpensation. Russian Cardiology Bulletin. 2025;(1):49-56
On the path to personalized cardiology: prospects of precise asse­ssment of cardiovascular risks and predictive-prognostic diagnostics. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):206-215
Diagnostic and prognostic pote­ntial of modern biomarkers in community-acquired pneumonia in children. Russian Journal of Preventive Medi­cine. 2025;(4):130-135
A comprehensive study of Alzheimer’s disease biomarkers in plasma and cere­brospinal fluid. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):43-53
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Diagnostic stra­tegies for post-COVID syndrome. Russian Journal of Preventive Medi­cine. 2025;(6):126-130
Spectral analysis in meta­bolomics of skin neoplasms. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):277-283
Morphological and immu­nohistochemical characteristics of skin specimens after isolated and combined inje­ctions of poly-L-lactic acid and hyaluronic acid. Plastic Surgery and Aesthetic Medi­cine. 2025;(3):50-62
Abstract:

The most important objective of modern neuroimaging is comparison of data on genotype and phenotype of brain gliomas. Radiogenomics as a new branch of science is devoted to searching for such relationships based on MRI and PET/CT parameters. The 2021 WHO classification of tumors of the central nervous system poses the most important tasks for physicians in assessment of biological behavior of tumors and their response to combined treatment. The review demonstrates the possibilities and prospects of preoperative MRI and PET/CT with amino acids in assessing the genetic profile of brain gliomas.

Keywords:

biomarkers
gliomas
radiogenomics
radiomics
PET/CT
perfusion
spectroscopy
methionine
T2/T2 Flair-mismatch

Authors:

Tyurina A.N.

Burdenko Neurosurgical Center

Vikhrova N.B.

Burdenko Neurosurgical Center

Batalov A.I.

Burdenko Neurosurgical Center

Kalaeva D.B.

Burdenko Center of Neurosurgery;
National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)

Shults E.I.

Research Practical Clinical Center of Diagnosis and Telemedicine Technologies

Postnov A.A.

Burdenko National Medical Scientific Center for Neurosurgery;
National Research Nuclear University MEPhI (Moscow Engineering Physics Institute);
Lebedev Physical Institute of the Russian Academy of Sciences

Pronin I.N.

Burdenko Neurosurgical Center

Received:

22.09.2022

Accepted:

11.10.2022

Close metadata

References:

  1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, Von Deimling A, Ellison DW. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro-Oncology. 2021;23(8):1231-1251. https://doi.org/10.1093/neuonc/noab106
  2. Vikhrova NB, Kalaeva DB, Postnov AA, Khokhlova E V., Konakova TA, Batalov AI, Pogosbekyan EL, Pronin IN. Dynamic 11C-methionine PET/CT in differential diagnosis of brain gliomas. Burdenko’s Journal of Neurosurgery. 2021;85(3):5-11. (In Russ.). https://doi.org/10.17116/neiro2021850315
  3. Tyurina AN, Pronin IN, Fadeeva LM, Batalov AI, Zakharova NE, Podoprigora AE, Shults EI, Kornienko VN. Protonnaya 3D-MR-spektroskopiya v diagnostike glial’nykh opukholey golovnogo mozga. Meditsinskaya vizualizatsiya. 2019;(3):8-18. (In Russ.). https://doi.org/10.24835/1607-0763-2019-3-8-18
  4. Jansen RW, van Amstel P, Martens RM, Kooi IE, Wesseling P, de Langen AJ, van Oordt CWMV der H, Jansen BHE, Moll AC, Dorsman JC, Castelijns JA, de Graaf P, de Jong MC. Non-invasive tumor genotyping using radiogenomic biomarkers, a systematic review and oncology-wide pathway analysis. Oncotarget. 2018;9(28):20134-20155. https://doi.org/10.18632/oncotarget.24893
  5. Lohmann P, Galldiks N, Kocher M, Heinzel A, Filss CP, Stegmayr C, Mottaghy FM, Fink GR, Jon Shah N, Langen KJ. Radiomics in neuro-oncology: Basics, workflow, and applications. Methods. 2021;188:112-121.  https://doi.org/10.1016/j.ymeth.2020.06.003
  6. Lasocki A, Gaillard F, Gorelik A, Gonzales M. MRI features can predict 1p/19q status in intracranial gliomas. American Journal of Neuroradiology. 2018;39(4):687-692.  https://doi.org/10.3174/ajnr.A5572
  7. Broen M, Smits M, Wijnenga M, Dubbink HJ, Anten M, Schijns O, Beckervordersandforth J, Postma AA, van den Bent MJ. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower grade glioma: A validation study. Neuro-oncology. 2018;20(10):1393-1399. https://doi.org/10.1093/neuonc/noy048/4953716
  8. Patel SH, Poisson LM, Brat DJ, Zhou Y, Cooper L, Snuderl M, Thomas C, Franceschi AM, Griffith B, Flanders AE, Golfinos JG, Chi AS, Jain R. T2—FLAIR mismatch, an imaging biomarker for IDH and 1p/19q status in lower-grade gliomas: A TCGA/TCIA project. Clinical Cancer Research. 2017;23(20):6078-6086. https://doi.org/10.1158/1078-0432.CCR-17-0560
  9. Johnson DR, Kaufmann TJ, Patel SH, Chi AS, Snuderl M, Jain R. There is an exception to every rule-T2-FLAIR mismatch sign in gliomas. Neuroradiology. 2019;61(2):225-227.  https://doi.org/10.1007/s00234-018-2148-4
  10. Law M, Young RJ, Babb JS, Peccerelli N, Chheang S, Gruber ML, Miller DC, Golfinos JG, Zagzag D, Johnson G. Gliomas: Predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. 2008;247(2):490-498.  https://doi.org/10.1148/radiol.2472070898
  11. Furtner J, Bender B, Braun C, Schittenhelm J, Skardelly M, Ernemann U, Bisdas S. Prognostic value of blood flow measurements using arterial spin labeling in gliomas. PLoS ONE. 2014;9(6). https://doi.org/10.1371/journal.pone.0099616
  12. Batalov AI, Zakharova NE, Pronin IN, Belyaev AY, Pogosbekyan EL, Goryaynov SA, Bykanov AE, Tyurina AN, Shevchenko AM, Solozhentseva KD, Nikitin PV, Potapov AA. 3D pCASL-perfusion in preoperative assessment of brain gliomas in large cohort of patients. Scientific Reports. 2022;12(1):1-7.  https://doi.org/10.1038/s41598-022-05992-4
  13. Zeng Q, Jiang B, Shi F, Ling C, Dong F, Zhang J. 3D pseudocontinuous arterial spin-labeling MR imaging in the preoperative evaluation of gliomas. American Journal of Neuroradiology. 2017;38(10):1876-1883. https://doi.org/10.3174/ajnr.A5299
  14. Xiao HF, Chen ZY, Lou X, Wang YL, Gui QP, Wang Y, Shi KN, Zhou ZY, Zheng DD, Wang DJJ, Ma L. Astrocytic tumour grading: a comparative study of three-dimensional pseudocontinuous arterial spin labelling, dynamic susceptibility contrast-enhanced perfusion-weighted imaging, and diffusion-weighted imaging. European Radiology. 2015;25(12):3423-3430. https://doi.org/10.1007/s00330-015-3768-2
  15. Batalov AI, Zakharova NE, Pogosbekyan EL, Fadeeva LM, Goryaynov SA, Baev AA, Shul’Ts EI, Chelushkin DM, Potapov AA, Pronin IN. Non-contrast ASL perfusion in preoperative diagnosis of supratentorial gliomas. Burdenko’s Journal of Neurosurgery. 2018;82(6):15-22. (In Russ.). https://doi.org/10.17116/neiro20188206115
  16. Solozhentseva K, Batalov A, Zakharova N, Goryaynov S, Pogosbekyan E, Pronin I. The Role of 3D-pCASL MRI in the Differential Diagnosis of Glioblastoma and Brain Metastases. Frontiers in Oncology. 2022;12:1-10.  https://doi.org/10.3389/fonc.2022.874924
  17. Batalov AI, Afandiev RM, Zakharova NE, Pogosbekyan EL, Shulgina AA, Kobyakov GL, Potapov AA, Pronin IN. 3D pseudo-continuous arterial spin labeling-MRI (3D PCASL-MRI) in the differential diagnosis between glioblastomas and primary central nervous system lymphomas. Neuroradiology. 2022;64(8):2021-2022. https://doi.org/10.1007/s00234-021-02888-4
  18. Batalov AI, Goryaynov SA, Zakharova NE, Solozhentseva KD, Kosyrkova AV, Potapov AA, Pronin IN. Prediction of intraoperative fluorescence of brain gliomas: Correlation between tumor blood flow and the fluorescence. Journal of Clinical Medicine. 2021;10(11). https://doi.org/10.3390/jcm10112387
  19. Kanazawa T, Minami Y, Jinzaki M, Toda M, Yoshida K, Sasaki H. Predictive markers for MGMT promoter methylation in glioblastomas. Neurosurgical Review. 2019;42(4):867-876.  https://doi.org/10.1007/s10143-018-01061-5
  20. Sibtain NA, Howe FA, Saunders DE. The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. Clinical Radiology. 2007;62(2):109-119.  https://doi.org/10.1016/j.crad.2006.09.012
  21. Kornienko VN, Pronin IN. Diagnosticheskaya nejroradiologiya. M.: IP Andreeva T.M.; 2006. (In Russ.).
  22. Choi C, Raisanen JM, Ganji SK, Zhang S, McNeil SS, An Z, Madan A, Hatanpaa KJ, Vemireddy V, Sheppard CA, Oliver D, Hulsey KM, Tiwari V, Mashimo T, Battiste J, Barnett S, Madden CJ, Patel TR, Pan E, Malloy CR, Mickey BE, Bachoo RM, Maher EA. Prospective longitudinal analysis of 2-hydroxyglutarate magnetic resonance spectroscopy identifies broad clinical utility for the management of patients with IDH-mutant glioma. Journal of Clinical Oncology. 2016;34(33):4030-4039. https://doi.org/10.1200/JCO.2016.67.1222
  23. Tietze A, Choi C, Mickey B, Maher EA, Ulhøi BP, Sangill R, Lassen-Ramshad Y, Lukacova S, Østergaard L, Von Oettingen G. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. Journal of Neurosurgery. 2018;128(2):391-398.  https://doi.org/10.3171/2016.10.JNS161793
  24. Zhou H, Vallières M, Bai HX, Su C, Tang H, Oldridge D, Zhang Z, Xiao B, Liao W, Tao Y, Zhou J, Zhang P, Yang L. MRI features predict survival and molecular markers in diffuse lower-grade gliomas. Neuro-Oncology. 2017;19(6):862-870.  https://doi.org/10.1093/neuonc/now256
  25. Rulseh AM, Vymazal J. Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients. Journal of Neuro-Oncology. 2020;146(1):157-162.  https://doi.org/10.1007/s11060-019-03357-y
  26. Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ. 2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: A systemic review and meta-analysis using individual patient data. Neuro-Oncology. 2018;20(12):1573-1583. https://doi.org/10.1093/neuonc/noy113
  27. Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, La Fougère C, Pope W, Law I, Arbizu J, Chamberlain MC, Vogelbaum M, Ellingson BM, Tonn JC. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology. 2016;18(9):1199-1208. https://doi.org/10.1093/neuonc/now058
  28. Kobyakov GL, Bekyashev AH, Golanov AV, Golanov AV, Konovalov AN, Naskhletashvili DR, Potapov AA, Rzaev DA, Ryzhova MV, Smolin AV, Trunin YY, Ulitin AY. Prakticheskiye rekomendatsii po lekarstvennomu lecheniyu otdel’nykh pervichnykh opukholey nervnoy sistemy. Zlokachestvennyye opukholi: Prakticheskiye rekomendatsii RUSSCO. 2018;8:83-99. (In Russ.).
  29. Galldiks N, Niyazi M, Grosu AL, Kocher M, Langen KJ, Law I, Minniti G, Kim MM, Tsien C, Dhermain F, Soffietti R, Mehta MP, Weller M, Tonn JC. Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients — a report of the PET/RANO group. Neuro-Oncology. 2021;23(6):881-893.  https://doi.org/10.1093/neuonc/noab013
  30. Verburg N, de Witt Hamer PC. State-of-the-art imaging for glioma surgery. Neurosurgical Review. 2021;44(3):1331-1343. https://doi.org/10.1007/s10143-020-01337-9
  31. Ninatti G, Kirienko M, Neri E, Sollini M, Chiti A. Imaging-based prediction of molecular therapy targets in NSCLC by radiogenomics and AI approaches: A systematic review. Diagnostics. 2020;10(6):359.  https://doi.org/10.3390/diagnostics10060359
  32. Haubold J, Demircioglu A, Gratz M, Glas M, Wrede K, Sure U, Antoch G, Keyvani K, Nittka M, Kannengiesser S, Gulani V, Griswold M, Herrmann K, Forsting M, Nensa F, Umutlu L. Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric 18F-FET PET-MRI and MR Fingerprinting. European Journal of Nuclear Medicine and Molecular Imaging. 2020;47(6):1435-1445. https://doi.org/10.1007/s00259-019-04602-2
  33. Yu P, Ning J, Xu B, Liu J, Dang H, Lin M, Feng X, Grimm R, Tian J. Histogram analysis of 11C-methionine integrated PET/MRI may facilitate to determine the O6-methylguanylmethyltransferase methylation status in gliomas. Nuclear Medicine Communications. 2019;40(8):850-856.  https://doi.org/10.1097/MNM.0000000000001039
  34. Qian J, Herman MG, Brinkmann DH, Laack NN, Kemp BJ, Hunt CH, Lowe V, Pafundi DH. Prediction of MGMT status for glioblastoma patients using radiomics feature extraction from 18F-DOPA-PET imaging. International Journal of Radiation Oncology Biology Physics. 2020;108(5):1339-1346. https://doi.org/10.1016/j.ijrobp.2020.06.073
  35. Wang Y, Kong Z, Lin Y, Jiang C, Li L, Liu Z, Wang Y, Dai C, Liu D, Qin X, Liu Z, Cheng X, Tian J, Ma W. 18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma. Cancer Imaging. 2019;19(1):58.  https://doi.org/10.1186/s40644-019-0246-0
  36. Matsui Y, Maruyama T, Nitta M, Saito T, Tsuzuki S, Tamura M, Kusuda K, Fukuya Y, Asano H, Kawamata T, Masamune K, Muragaki Y. Prediction of lower-grade glioma molecular subtypes using deep learning. Journal of Neuro-Oncology. 2020;146(2):321-327.  https://doi.org/10.1007/s11060-019-03376-9
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.